Abstract: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role.

Abstract: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role.

Abstract: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role.

Abstract: A method for increasing the weight gain and/or improving the feed utilization efficiency and/or increasing the lean body mass and/or decreasing birth mortality rate and increasing post-natal survival rate of livestock comprises the administration to livestock of an effective, non-toxic amount of a compound of formula (I), or a veterinarily acceptable acid addition salt thereof: ##STR1## wherein R.sup.1 is phenyl (C.sub.1-6) alkyl or optionally substituted C.sub.1-6 alkyl, andW is optionally substituted phenyl, a heterocyclyl group, or phenoxymethyl optionally substituted on the phenyl group. Certain compounds of formula (I) are novel.

Abstract: A method for inceasing the weight gain and/or improving the feed utilization efficiency and/or increasing the lean body mass and/or decreasing birth mortality rate and increasing post-natal survival rate of livestock comprises the administration to livestock of an effective, non-toxic amount of a compound of formula (I), or a veterinarily acceptable acid addition salt thereof: ##STR1## wherein R.sup.1 is phenyl (C.sub.1-6)alkyl or optionally substituted C.sub.1-6 alkyl, andW is optionally substituted phenyl, a heterocyclyl group, or phenoxymethyl optionally substituted on the phenyl group. Certain compounds of formula (I) are novel.

Abstract: Compounds of formula (I): ##STR1## wherein ##STR2## is a 5-membered heterocyclic group having a 6-.pi.electron system, the five ring atoms being either(a) one carbon atom and four atoms selected from carbon and nitrogen,(b) two carbon atoms, two nitrogen atoms and one atom selected from oxygen and sulphur, or(c) four carbon atoms and one atom selected from oxygen and sulphurand R.sup.1 is a substituent on a carbon or nitrogen of ##STR3## selected from C.sub.1-20 alkyl, C.sub.2-8 alkenyl aryl, aralkyl and heterocyclyl, each of which may optionally be substituted; hydrogen and C.sub.3-7 cycloalkyl,and, where appropriate, R.sup.2 is a substituent on a carbon or nitrogen of ##STR4## and when present is the same or different to R.sup.1 and is selected from C.sub.1-20 alkyl, C.sub.2-8 alkenyl, aryl, aralkyl and heterocyclyl each of which may optionally be substituted; hydrogen and C.sub.3-7 cycloalkyl, have antibacterial and antimycoplasmal activity.

Abstract: A compound of the formula (I) ##STR1## wherein R is a group ##STR2## R.sup.1 is hydrogen, phenyl, C.sub.1-20 alkyl, C.sub.2-8 alkenyl or C.sub.2-8 alkynyl each of which may optionally be substituted; or C.sub.3-7 cycloalkyl,X is a divalent group --Y--C.dbd.C--, andY is oxygen or sulphur,have antibacterial and/or antimycoplasmal activity.

Abstract: Esters of an acid of formula: ##STR1## which is termed "monic acid" have activity against Gram-positive and Gram-negative organisms.

Abstract: Compounds of formula (I): ##STR1## wherein Y is halogen,R.sup.1 is hydrogen, a salt forming radical, alkyl or aralkyl,have antibacterial and/or antimycoplasmal activity.

Abstract: Compounds of formula (II): ##STR1## wherein R is C.sub.1-20 alkyl; C.sub.3-8 cycloalkyl; C.sub.3-20 alkenyl; aralkyl; cycloalkylalkyl; heterocyclyl or heterocyclylalkyl; each being substituted with formyl; ##STR2## have activity against human and veterinary bacteria and mycoplasma. They may be produced by conventional methods and are used in conventional formulations.

Abstract: Compounds of formula (II): ##STR1## in which R represents a pharmaceutically acceptable ester-forming radical have antibacterial and antimycoplasmal activity. These compounds are produced by photo-oxidation of the corresponding 13-hydroxy compounds, optionally after having protected the glycol moiety.

Abstract: Compounds of formula (II): ##STR1## in which Y represents ##STR2## and R.sub.0 represents a C.sub.2-20 alkyl, C.sub.3-8 cycloalkyl, C.sub.4-20 alkenyl, arakyl, cycloalkylalkyl, heterocyclyl or heterocyclylalkyl group, which is substituted by a hydroxyiminohydrazono- or semicarbazono group, have activity against human and veterinary bacteria and mycoplasma. They may be produced by conventional methods and are used in conventional formulations.

Abstract: Esters of an acid of formula: ##STR1## which is termed "monic acid" have activity against Gram-positive and Gram-negative organisms.

Abstract: Compounds of formula (II): ##STR1## Z represents a divalent radical derived from a C.sub.1-20 alkane, C.sub.3-8 cycloalkane, C.sub.2-20 alkene, arene, aralkane, cycloalkylalkane, heterocycle, or heterocylylalkane; and R.sup.x and R.sup.y are the same or different and each represent (a) hydrogen, or (b) C.sub.1-20 alkyl, C.sub.2-8 alkenyl, either of which may be optionally substituted with C.sub.3-7 cycloalkyl, halogen, carboxy, C.sub.1-6 alkoxycarbonyl, carbamyl, aryl, heterocyclyl, hydroxy, C.sub.1-6 alkanoyloxy, amino, mono- or di-(C.sub.1-6) alkylamino; or (c) C.sub.3-7 cycloalkyl optionally substituted with C.sub.1-6 alkyl; or (d) aryl; or (e) heterocyclyl; or (f) R.sup.x and R.sup.y together with the nitrogen atom to which they are attached represent a C.sub.5-7 heterocyclic ring, are useful as antibacterial and antimycoplasma agents.

Abstract: A ketone of formula (II): ##STR1## wherein Y represents ##STR2## and R represents a C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, aryl, aralkyl or cycloalkylalkyl group, optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, carboxy or C.sub.1-6 alkoxy carbonyl, or represents a 5 or 6 membered heterocyclic group containing a nitrogen, oxygen or sulphur atom, has antibacterial and antimycloplasmal activity and is of value in the treatment of bacterial and mycoplasma-induced human and veterinary diseases.

Abstract: Esters of an acid of formula: ##STR1## which is termed "monic acid" have activity against Gram-positive and Gram-negative organisms.

Abstract: This invention relates to antibacterial compounds and in particular to a class of esters which have antibacterial activity against certain Gram-positive and Gram-negative organisms, and also possess antimycoplasmal activity. The compounds are therefore of value in the treatment of human and veterinary infections.

Abstract: Esters of an acid of formula: ##STR1## which is termed "monic acid" have activity against Gram-positive and Gram-negative organisms.

Abstract: Esters of an acid of formula: ##STR1## which is termed "monic acid" have activity against Gram-positive and Gram-negative organisms.